The deal is believed to enforce VistaGen’s stem cell technology-based drug rescue activities using Synterys’ medicinal chemistry expertise.
VistaGen’s drug rescue initiatives comprise its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to develop new chemical variants (drug rescue variants) of small molecule drug candidates that were discontinued because of toxicity issues.
VistaGen CEO Shawn Singh said the agreement supports the drug rescue applications of their Human Clinical Trials in a Test Tube platform.
"This strategic collaboration represents another important link in the ecosystem we are building around our cutting-edge technologies and innovations from industry and academia focused on transforming drug development," Singh added.